Merck is reevaluating the design of its Phase IIb trial for I-vation TA that it’s conducting with SurModics, Inc. and therefore suspending enrollment of new patients in the trial. The decision follows recent study results comparing laser treatment and intravitreal injections of triamcinolone acetonide (TA) in patients with diabetic macular edema (DME).     Merck’s Phase IIb trial is intended to evaluate the safety and efficacy of SurModics’ I-vation TA in patients with DME. The trial s...